Buchanan Ingersoll & Rooney Represents TypeZero in Sale to DexCom
WASHINGTON, D.C. – August 31, 2018 – Buchanan Ingersoll & Rooney represented TypeZero Technologies, Inc., the inventor of the inControl Diabetes Management Platform, in its sale to DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes. Kevin L. Passarello, a shareholder in the firm’s Corporate Finance section, led the transaction along with David Monaghan, shareholder.
“We have represented TypeZero from the company’s inception at the University of Virginia and have watched them develop important, one-of-a-kind technologies for diabetes patients. It’s always exciting when a company moves successfully from the conceptual, academic realm into a tangible, commercial context – especially when it can benefit consumers with real problems,” noted Passarello.
“I’m grateful to Kevin for his guidance and counsel in advance of and throughout the acquisition process. He’s been our trusted advisor for the past four years, and helped us to realize our clinical mission and corporate vision,” said Chad Rogers, TypeZero’s CEO.
The TypeZero platform includes advisory applications for smart insulin pens and smartphone-based artificial pancreas systems that automatically regulate insulin delivery, drastically reduce hypoglycemia, and significantly improve blood glucose levels. The platform can also advise Type 2 patients about lifestyle and food management to optimize disease management.
The terms of the DexCom transaction were not disclosed.